Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:Q06643 (non-Hodgkin's lymphoma)
 11,307 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Seven patients with low-grade non-Hodgkin's lymphoma were treated with a combination of a murine monoclonal antibody directed against the B-cell-specific antigen CD19 (CLB-CD19), given twice weekly, and continuous infusion of low-dose recombinant interleukin-2 (rIL-2). We demonstrated stable serum CLB-CD19 levels throughout the 12 weeks of treatment, and homing of the antibody into the tumour sites. A variable degree of antigenic modulation was noted. Prolonged treatment resulted in a sustained increase in the number of natural killer cells in the circulation with enhanced cytotoxic capacity, including antibody-dependent cellular cytotoxicity. During the first weeks of treatment, T cell activation occurred in the majority of patients. Toxicity was related to the rIL-2 treatment and consisted of transient constitutional symptoms and a flu-like syndrome without organ dysfunction. A partial remission occurred in one patient, and in another patient who was primarily leukaemic a greater than 50% reduction of circulating B cells was noted. An antitumour effect occurred early during treatment and could not be related to rIL-2-induced modulation of natural killer cell or T lymphocyte activation.
 ...
PMID:Treatment of low-grade non-Hodgkin's lymphoma with continuous infusion of low-dose recombinant interleukin-2 in combination with the B-cell-specific monoclonal antibody CLB-CD19. 753 Jan 70

Adverse reactions to interferon-alpha (IFN-alpha) therapy include flu-like syndrome, bone marrow suppression, neurotoxic effects, and autoimmunity. A slight increase in triglyceride levels has been described less frequently during IFN-alpha administration. The incidence of IFN-alpha-induced hypertriglyceridemia seems variable, and there are no clear data on how to treat it. We report the effect of long-term (more than 12 months) IFN-alpha treatment on triglyceride levels in 43 patients suffering from hairy cell leukemia (18), multiple myeloma (10), chronic myelogenous leukemia (6), cryoglobulinemia (5), non-Hodgkin's lymphoma (3), and Sezary syndrome (1). Hypertriglyceridemia was found in 6 patients (15%). In 3 patients, gemfibrozil restored normal triglyceride values. This study suggests that hypertriglyceridemia is a minor side effect of long-term IFN-alpha therapy and that gemfibrozil might be considered the treatment of choice.
 ...
PMID:Hypertriglyceridemia during long-term interferon-alpha therapy in a series of hematologic patients. 918 61

Lifestyle, sexual history, and medical history characteristics were analyzed as risk factors for non-Hodgkin's lymphoma (NHL) in a population-based case-control study of 1593 subjects with NHL and 2515 control subjects conducted in the San Francisco Bay Area between 1988 and 1995. The results for homosexual men, 312 with NHL and 420 control subjects, showed that HIV infection was associated with a 20-fold increased risk for NHL. Among HIV-positive homosexual men, after adjustment for other factors, those that were associated with a reduced risk for NHL were frequency of receptive anal intercourse between the ages of 20 and 29 (1 to 9 times: OR = 0.63; > or = 10 times: OR = 0.37; trend: p = 0.02), allergy to grass, hay, leaves, plants and pollen (OR = 0.35, CI = 0.19 to 0.64), number of bee or wasp stings (1 to 3 times: OR = 0.65; > or =4 times: OR = 0.56; trend: p = 0.07), use of Tagamet (cimetidine) for 4 consecutive weeks or longer (OR = 0.39, CI = 0.17 to 0.89), vaccination against influenza (OR = 0.41, CI = 0.23 to 0.74), and lifetime frequency of amphetamine use (1 to 19 times: OR = 0.59; > or =20 times: OR = 0.38; trend: p = 0.003). Among HIV-negative homosexual men, after adjustment for other factors, factors that were associated with NHL status were frequency of receptive anal intercourse between the ages of 20 and 29 (1 to 9 times: OR = 0.39; > or =10 times: OR = 0.20; trend: p = 0.001), nonmedication allergies (OR = 0.43, CI = 0.21 to 0.89), vaccination against poliomyelitis at <10 years (OR = 0.41, CI = 0.17 to 0.99), and having five or more siblings (OR = 3.6, CI = 1.7 to 7.7). An increased immunosuppressive effect of seminal fluid on sensitive rectal tissue and support from earlier work suggesting that HIV-related lymphomas may be outgrowths of antigen-driven B cells provide a possible mechanism for the results of this study. The role of allergic reactions in NHL is likely to be complex and may be related to B-cell differentiation. These associations may provide insight into an antigen-driven process early in lymphomagenesis.
 ...
PMID:Non-Hodgkin's lymphoma in HIV-positive and HIV-negative homosexual men in the San Francisco Bay Area: allergies, prior medication use, and sexual practices. 925 56

Interferon-alfa in combination with cytotoxic chemotherapy has been shown to be effective in treating certain types of non-Hodgkin's lymphoma (NHL) (1). However, there is no published data on upfront induction treatment of aggressive NHL with IFN-alfa containing regimens. Studies have also shown that one can overcome regrowth resistance by administering mid-cycle agents which slow tumor proliferation between courses of cytotoxic therapy (2). Based on this, we treated 32 consecutive patients between 1/93 and 9/96 with a regimen containing cyclophosphamide 750 mg/m2, mitoxantrone 12 mg/m2, and teniposide 60 mg/m2 IV on day 1 with prednisone 100 mg PO given on days 1-5. On day 15, patients received vincristine 1.4 mg/m2 (2 mg max.) and bleomycin 10 units/m2 IV. Interferon-alfa-2b 5x10(6) units/m2 SQ was administered on days 22-26. The median age was 55 (range 26-83), M:F ratio was 2.5:1, and the median International Prognostic Index was 2. 38% of patients had stages I-II and 62% had stages III-IV disease. Fifty-nine percent of the patients achieved a complete response, 22% a partial response, and 19% had progressive disease. The overall survival (OS) was 81% and the progression free survival (PFS) was 56% at 4.3 years. There were no severe (grade IV) hematologic, flu-like, GI and infectious toxicities from IFN-alpha. Leukopenia was the main severe toxicity related to the chemotherapy regimen (days 1-15), but not IFN-alpha. Severe infection secondary to the chemotherapy regimen occurred in one patient. Interferon-alfa-2b and mid-cycle chemotherapy added to an anthracycline based regimen is effective induction treatment for patients with aggressive NHL. The OS and PFS using this regimen, based on regrowth resistance, appears to be at least as or more effective than CHOP therapy for this group of patients. Severe toxicities were rare.
 ...
PMID:Effectiveness of interferon-alfa and mid-cycle chemotherapy added to an anthracycline-based regimen in the treatment of aggressive non-Hodgkin's lymphoma. 1142 54

Rituximab, a mouse-human chimeric anti-CD20 monoclonal antibody, induces apoptosis in B cell non-Hodgkin's lymphoma (B-NHL) cells, in addition to lysis by complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity. A group of 12 patients with relapsed CD20+ B-NHL were enrolled in a phase I study; 4 received rituximab 250 mg/m2 and 8 375 mg/m2 once weekly for 4 weeks. Grade 1 or 2 infusion-related toxicity such as 'flu-like symptoms and skin reactions were observed. Of the 11 patients eligible for study enrollment, 2 achieved a complete response (CR) and 5 a partial response (PR). The T 1/2 of rituximab was 445+/-361 h, and serum rituximab levels were measurable at 3 months. Thereafter, 90 relapsed patients with indolent B-NHL or mantle cell lymphoma (MCL) were enrolled in a phase II study and received rituximab 375 mg/m2x4 weekly infusions. A central pathology review and an extramural review disclosed that 13 patients were ineligible for final analysis. Factors affecting response and progression-free survival (PFS) were analyzed in the remaining 77 patients. The overall response rate (ORR) in indolent B-NHL and MCL was 61% (37/ 61, 95% CI 47-73%) and 46% (6/13, 95% CI 19-75%), respectively. The median PFS time was 245 days in indolent B-NHL and 111 days in MCL patients. Multivariate analysis revealed that the ORR was affected by the number of prior regimens (P=0.018) and that the PFS was affected by the following three factors: disease type (P = 0.000), presence of extranodal lesions (P=0.001). and number of prior regimens (P=0.007). The PFS times of patients with higher serum rituximab concentrations at day 14 (> or =70 microg/ml) and at 3 months (> or =10 microg/ml) were significantly longer than those of patients with lower concentrations (P=0.006 and P=0.0001, respectively). In conclusion, rituximab is more effective in indolent B-NHL than in MCL. Several prognostic factors and serum rituximab concentrations are useful for predicting the therapeutic efficacy.
 ...
PMID:Clinical trials of a mouse-human chimeric anti-CD20 monoclonal antibody (rituximab) for B cell non-Hodgkin's lymphoma in Japan. 1158 74

Communicable respiratory viruses as a causative factor of infectious complication in hemoblastosis and myelodepression were investigated in 51 patients (aplastic anemia--3, multiple myeloma--10, different patterns of acute leukemia--16, chronic leukemia--8 and non-Hodgkin's lymphoma--14). Our clinical evidence obtained with the aid of polymerase chain reaction featured genomes of adenoviruses, influenza A and B viruses, respiratory-scintillating virus and coronaviruses. On the whole, respiratory viral infections were detected in 27 (52.9%) patients: adenoviruses--23.5%, coronaviruses--13.7%, influenza A and B--5.9% and respiratory-scintillating virus--3.9%. In many cases, herpes was associated with viral respiratory infection. That pathology was most often triggered by severe neutropenia induced by chemotherapy.
 ...
PMID:[Molecular biology investigation of respiratory viruses as a factor of infectious complications in hemoblastosis and myelodepression]. 1702 15

black triangle (131)I tositumomab is a radiolabelled murine anti-CD20 monoclonal antibody that binds specifically to the CD20 antigen on normal and malignant B lymphocytes. It has antitumour activity as a result of emission of beta particles, and activation of antibody-dependent cellular and complement-mediated cytotoxicity. black triangle (131)I tositumomab monotherapy consistently produced objective response rates of >or=60% in patients with relapsed or refractory, low grade or transformed low grade non-Hodgkin's lymphoma (NHL) in clinical trials. 62% of patients responded to retreatment in 1 small trial. black triangle In 2 studies, objective and complete response rates were higher and overall durations of response were significantly longer in patients treated with (131)I tositumomab compared with their last chemotherapy regimen. black triangle High dose (131)I tositumomab combined with autologous stem cell transplant produced an objective response rate of 86% in relapsed or refractory patients. black triangle (131)I tositumomab alone or in combination with fludarabine achieved an objective response rate of 100% in 2 preliminary reports in patients with previously untreated NHL. black triangle The dose-limiting toxicity of (131)I tositumomab is reversible myelosuppression, with approximately 18% of patients requiring haematological support in combined trial data. Other nonhaematological toxicities occur in approximately 20 to 40% of patients and include mild to moderate flu-like symptoms.
 ...
PMID:131I tositumomab. 1803 70

Short- and long-term anti tumor necrosis factor-alpha (TNF-alpha) therapy in Crohn's disease is generally well tolerated. However, clinicians must be vigilant for the occurrence of infrequent but serious events. Antibodies to infliximab interfere with the safety and efficacy of the drug and may lead to infusion reactions, loss of response, and delayed serum sickness-like reactions. The optimal strategy to overcome the production of antibodies is systematic maintenance treatment. The most effective way to minimize the risk of opportunistic infection is to vaccinate the patients and to avoid the use of corticosteroids. All patients should receive varicella vaccination, annual influenza vaccination (also pandemic influenza A - H1N1), and pneumococcal vaccination every 3 to 5 years. In addition, HPV vaccine should be administered to young females, and hepatitis B vaccine to HBV seronegative patients. Unlike corticosteroids, infliximab does not pose an increased risk for serious infection. Treatment with anti TNF-alpha agents increases the risk of activation of latent TB. Therefore, all patients should be screened for TB infection before starting with therapy. The use of anti TNF-alpha agents in combination with immunomodulators is associated with an increased risk of non-Hodgkin's lymphoma, but the absolute rate remains low. There is no evidence that other malignancies and death rates in patients treated with anti TNF-alpha strategies are increased. Reported data from 300 pregnant women treated with infliximab have not shown any untoward effects of treatment on pregnancy outcome.
 ...
PMID:How to improve the safety of biologic therapy in Crohn's disease. 2038 47

In the last few years, plants have become an increasingly attractive platform for recombinant protein production. This builds on two decades of research, starting with transgenic approaches to develop oral vaccines in which antigens or therapeutics can be delivered in processed plant biomass, and progressing to transient expression approaches whereby high yields of purified targets are administered parenterally. The advantages of plant-based expression systems include high scalability, low upstream costs, biocontainment, lack of human or animal pathogens, and ability to produce target proteins with desired structures and biological functions. Using transgenic and transient expression in whole plants or plant cell culture, a variety of recombinant subunit vaccine candidates, therapeutic proteins, including monoclonal antibodies, and dietary proteins have been produced. Some of these products have been tested in early phase clinical trials, and show safety and efficacy. Among those are mucosal vaccines for diarrheal diseases, hepatitis B and rabies; injectable vaccines for non-Hodgkin's lymphoma, H1N1 and H5N1 strains of influenza A virus, and Newcastle disease in poultry; and topical antibodies for the treatment of dental caries and HIV. As lead plant-based products have entered clinical trials, there has been increased emphasis on manufacturing under current Good Manufacturing Practice (cGMP) guidelines, and the preparation and presentation to the relevant government agencies of regulatory packages.
 ...
PMID:Clinical development of plant-produced recombinant pharmaceuticals: vaccines, antibodies and beyond. 2134 17

Along with the depreciation of tobacco as a source of nicotine-containing commercial products, the increase of its appreciation as a potential producer of recombinant therapeutical proteins can be observed. Two species of tobacco--Nicotiana tabacum L. and N. benthamiana are easily grown by well established methods of field or green-house cultivation or cell culture, yield high biomass and soluble protein content, can be easily transformed by several methods and are not food for humans or feed for animals. Expression of foreign proteins, including vaccines, can be achieved in those plants either through stable transformation of nuclear or plastid (chloroplast) genomes or by transient transformation using infection with plant virus or bacteria--Agrobacterium tumefaciens (agroinfiltration). The most advanced mode of agrofiltration termed magnifection, which combines benefits of virus and Agrobacterium and depends on using Agrobacterium with viral pro-vectors, enables high-yield and rapid expression of therapeutical proteins, even in a few days, and can be employed on an industrial scale. Expression of many antigenic proteins, which may serve as antiviral, antibacterial, antiprotozoan and anticancer vaccines, and additionally a few autoantigens designed for the treatment of autoimunogenic diseases, like diabetes, have been achieved in tobacco. To date, a vaccine against Newcastle virus disease in poultry produced by tobacco cell culture has been approved for commercial application and several other vaccines are in advanced stage of development. The possibility of a high-level production of vaccines in tobacco against pandemic influenza or anthrax and plague due to a bioterroristic attack, as well as of individualised anticancer vaccines against non-Hodgkin's lymphoma (NHL) in a much shorter period of time than by traditional methods became realistic and hence caused increased interest in tobacco as a high-efficient producer of vaccines not only of specialistic biotechnology firms but also a big pharmaceutical corporation and a department of defence.
 ...
PMID:[Tobacco--a highly efficient producer of vaccines]. 2136 Sep 63


<< Previous 1 2 3 Next >>